The power of lifestyle interventions to prevent cardiovascular diseases. Tuomilehto J. Conference on Cardiovascular Diseases (Madrid: Ministry of Health and Social Policy; 2010).
Insulin intensification : the usage of premixed insulin after basal fails mataharitimoer MT
Insulin intensification : the usage of premixed insulin after basal fails
EDDY SUPRIADI, MD | MARZOEKI MAHDI , MD. HOSPITAL.BOGOR
Disampaikan pada acara PIT VI IDI Kota Bogor | 9 Nopember 2013
Why cholesterol has a split personality and how the fitness sector can help tackle the growing number of people with high cholesterol levels through positive dietary and lifestyle changes.
Insulin intensification : the usage of premixed insulin after basal fails mataharitimoer MT
Insulin intensification : the usage of premixed insulin after basal fails
EDDY SUPRIADI, MD | MARZOEKI MAHDI , MD. HOSPITAL.BOGOR
Disampaikan pada acara PIT VI IDI Kota Bogor | 9 Nopember 2013
Why cholesterol has a split personality and how the fitness sector can help tackle the growing number of people with high cholesterol levels through positive dietary and lifestyle changes.
Alcohol and chronic diseases: complex relations. Guillemont J. Conference on Cardiovascular Diseases (Madrid: Ministry of Health and Social Policy; 2010).
Dr Peter Goethals: Sport en plotse dood - Screening elektrocardiogram (BHC Sy...Brussels Heart Center
Peter Goethals: Sport en plotse dood - Screening elektorcardiogram voor jonge competitiesporters (BHC Symposium 2012)
2/100.000 per jaar is de plotse dood bij de jonge sporten, nog niet de atleet, zoals verschenen in de statistieken van de italiaanse sporters, er is een screening voor inschrijven in de sportclubs sedert 30 jaar
Sporters uit amerika, high school en college competitive athletes, 14 à 22 jaar.
Als je sport doet dan is je risico op plotse dood 2.5 keer groter dan bij niet sporters maar het is gebleken dat dit risico kan oplopen tot 100 maal als je een incomplete penetratie hebt van een aangeboren cardiovasculaire ziekte omdat het lichaam wordt blootgesteld en het fragiel is.
Multidisciplinary care: a perspective from diagnosis and treatment of rare cancers. Casali P. Technical Conference: Multidisciplinary Care in Cancer as a model of health care quality (Madrid: Ministry of Health and Social Policy, 2010)
La mejor evidencia junto a la mejor organización: el reto de la coordinación profesional en atención oncológica. Sánchez de Toledo J. Jornada Técnica: Atención Multidisciplinar en Cáncer como modelo de calidad asistencial (Madrid: Ministerio de Sanidad y Política Social, 2010)
More Related Content
Similar to The power of lifestyle interventions to prevent cardiovascular diseases
Alcohol and chronic diseases: complex relations. Guillemont J. Conference on Cardiovascular Diseases (Madrid: Ministry of Health and Social Policy; 2010).
Dr Peter Goethals: Sport en plotse dood - Screening elektrocardiogram (BHC Sy...Brussels Heart Center
Peter Goethals: Sport en plotse dood - Screening elektorcardiogram voor jonge competitiesporters (BHC Symposium 2012)
2/100.000 per jaar is de plotse dood bij de jonge sporten, nog niet de atleet, zoals verschenen in de statistieken van de italiaanse sporters, er is een screening voor inschrijven in de sportclubs sedert 30 jaar
Sporters uit amerika, high school en college competitive athletes, 14 à 22 jaar.
Als je sport doet dan is je risico op plotse dood 2.5 keer groter dan bij niet sporters maar het is gebleken dat dit risico kan oplopen tot 100 maal als je een incomplete penetratie hebt van een aangeboren cardiovasculaire ziekte omdat het lichaam wordt blootgesteld en het fragiel is.
Multidisciplinary care: a perspective from diagnosis and treatment of rare cancers. Casali P. Technical Conference: Multidisciplinary Care in Cancer as a model of health care quality (Madrid: Ministry of Health and Social Policy, 2010)
La mejor evidencia junto a la mejor organización: el reto de la coordinación profesional en atención oncológica. Sánchez de Toledo J. Jornada Técnica: Atención Multidisciplinar en Cáncer como modelo de calidad asistencial (Madrid: Ministerio de Sanidad y Política Social, 2010)
La mejor evidencia junto a la mejor organización: el reto de la coordinación profesional en atención oncológica. Ortiz H. Jornada Técnica: Atención Multidisciplinar en Cáncer como modelo de calidad asistencial (Madrid: Ministerio de Sanidad y Política Social, 2010)
La mejor evidencia junto a la mejor organización: el reto de la coordinación profesional en atención oncológica. Barnadas A. Jornada Técnica: Atención Multidisciplinar en Cáncer como modelo de calidad asistencial (Madrid: Ministerio de Sanidad y Política Social, 2010)
Experiencias y percepción de la atención integral de los pacientes con cáncer. Oriol Díaz de Bustamante I. Jornada Técnica: Atención Multidisciplinar en Cáncer como modelo de calidad asistencial (Madrid: Ministerio de Sanidad y Política Social, 2010)
Experiencias y percepción de la atención integral de los pacientes con cáncer. Moreno Marín P. Jornada Técnica: Atención Multidisciplinar en Cáncer como modelo de calidad asistencial (Madrid: Ministerio de Sanidad y Política Social, 2010)
La mejor evidencia junto a la mejor organización: el reto de la coordinación profesional en atención oncológica. Medina JA. Jornada Técnica: Atención Multidisciplinar en Cáncer como modelo de calidad asistencial (Madrid: Ministerio de Sanidad y Política Social, 2010)
Experiencias y percepción de la atención integral de los pacientes con cáncer. Fisas Armengol A. Jornada Técnica: Atención Multidisciplinar en Cáncer como modelo de calidad asistencial (Madrid: Ministerio de Sanidad y Política Social, 2010)
La mejor evidencia junto a la mejor organización: el reto de la coordinación profesional en atención oncológica. Ferro T. Jornada Técnica: Atención Multidisciplinar en Cáncer como modelo de calidad asistencial (Madrid: Ministerio de Sanidad y Política Social, 2010)
La mejor evidencia junto a la mejor organización: el reto de la coordinación profesional en atención oncológica. Díaz Mediavilla J. Jornada Técnica: Atención Multidisciplinar en Cáncer como modelo de calidad asistencial (Madrid: Ministerio de Sanidad y Política Social, 2010)
La mejor evidencia junto a la mejor organización: el reto de la coordinación profesional en atención oncológica. Ignacio A. Jornada Técnica: Atención Multidisciplinar en Cáncer como modelo de calidad asistencial (Madrid: Ministerio de Sanidad y Política Social, 2010)
Risk Assessment and Management of Cardiovascular Diseases - an English Approach. Lynam E. Conference on Cardiovascular Diseases (Madrid: Ministry of Health and Social Policy; 2010).
Cardiovascular disease inequalities: causes and consequences. Capewell S. Conference on Cardiovascular Diseases (Madrid: Ministry of Health and Social Policy; 2010).
Addressing cardiovascular disease at EU level: tangible plans for the future. Hübel M. Conference on Cardiovascular Diseases (Madrid: Ministry of Health and Social Policy; 2010).
The impact of eHealth on Healthcare Professionals and Organisations: The Impact of ICT at Kaiser Permanente. Wiesenthal A. eHealth week 2010 (Barcelona: CCIB Convention Centre; 2010)
The impact of eHealth on Healthcare Professionals and Organisations: A National Perspective. Eccles S. eHealth week 2010 (Barcelona: CCIB Convention Centre; 2010)
The impact of eHealth on Healthcare Professionals and Organisations: Health Information Management Systems in Modern Health Care. Shemer J. eHealth week 2010 (Barcelona: CCIB Convention Centre; 2010)
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
The power of lifestyle interventions to prevent cardiovascular diseases
1. The power of lifestyle interventions
to prevent cardiovascular disease
and type 2 diabetes.
Prof. Jaakko Tuomilehto
Department of Public Health,
University of Helsinki
2. DEVELOPED COUNTRIES – year 2000
Deaths attributable to 15 leading causes
Cardiovascular diseases
Malignant neoplasms
Injuries
Respiratory diseases
Digestive diseases
Respiratory infections
Neuropsychiatric disorders
Diabetes mellitus 98% of all deaths
Diseases of the genitourinary system attributable to
Perinatal conditions 15 leading causes
Tuberculosis
Nutritional/endocrine disorders
Other neoplasms
Congenital abnormalities
Musculoskeletal diseases
0 1000 2000 3000 4000 5000 6000 7000
Source: WHR 2002
Number of deaths (000s)
3. DEVELOPED COUNTRIES – year 2000
Deaths attributable to selected leading risk factors
Blood pressure
Tobacco
Cholesterol
High Body Mass Index
Low fruit and vegetable intake
Physical inactivity
Alcohol
Urban air pollution
Lead exposure
Occupational carcinogens
Illicit drugs
Unsafe sex
Occupational particulates
Occupational risk factors for injury
0 500 1000 1500 2000 2500 3000
Number of deaths (000s)
4. WHO MONICA Project
Monitored
10 year CHD trends from mid 1980s – mid 1990s
across 37 populations in 21 countries
166,000 events registered during 371 populationyears
0
Fall in CHD mortality rates 27%
-2 0 0 0 0
Event rates 21%
-4 0 0 0 0
(incidence ≅ risk factors)
-6 0 0 0 0
Case fatality –6%
≅
(≅ treatments)
-8 0 0 0 0
Tunstall-Pedoe et al. Contribution of trends in survival & coronary
event rates to changes in CHD mortality Lancet 1999 353 1547
5. IMPACT Model: Main Components
Cholesterol BMI & Diabetes
RISK Blood Pressure Activity
Smoking Physical
F FACTORS Blood Pressure
Age & Sex
Patient
Groups AMI Angina Heart Failure 2' Prevention
CABG/PTCA
TREATMENTS Medical Therapy
Medical surgery
OUTCOMES Death Survival
Unal, Critchley & Capewell
Unal,
Circulation 2004 109(9) 11017
1101
6. Mortality per
100 000 700
start of the North Karelia Project
population
600
extension of the Project nationally
Age-adjusted CHD
500
mortality rate in
North Karelia and
North Karelia
400
the whole of
Finland.
300
Men 35-64 years - 82 %
200
All Finland
during 1969 - 2002.
- 75%
100
69 72 75 78 81 84 87 90 93 96 99 2002
Year
29
7. Diastolic Blood Pressure
mmHg
Women 30-59 Years
95
90
North Karelia
Kuopio
Turku/Loimaa
85
Helsinki/Vantaa
Oulu Province
80
Lapland
75
1972 1977 1982 1987 1992 1997 2002
8. Serum cholesterol in Finnish men aged 25-64
years
mmol/l
7
6,5
North Karelia
Kuopio
Turku/Loimaa
6
Helsinki/Vantaa
Oulu
5,5
Lapland
5
1982 1987 1992 1997 2002 2007
9. CHANGE IN SERUM CHOLESTEROL IN
FINLAND 1982-2002*
MEN
Miehet
0,1
PUFA
0 Diet cholesterol
Dietaarinen
kolesteroli
-0,1
SFA
-0,2
mmol/l
Keys
-0,3
SFA+trans
-0,4
Keys (trans) **
-0,5 Mitattu S-Kol
Measured serum
-0,6 cholesterol
1982 1992 2002
10. CHANGE IN SERUM CHOLESTEROL IN
FINLAND 1982-2002*
WOMEN
Naiset
0,1
PUFA
0 Diet cholesterol
Dietaarinen
kolesteroli
-0,1
SFA
mmol/l
-0,2
Keys
-0,3
SFA+trans
-0,4
Keys (trans) **
-0,5
Mitattu S-Kol
Measured serum
-0,6 cholesterol
1982 1992 2002
*
11. Use of butter on bread
%
(men 30-59)
100
North Karelia
90
Kuopio
80
Turku/Loimaa
70
Helsinki/Vantaa
Oulu
60
Lapland
50
40
30
20
10
0
1972 1977 1982 1987 1992 1997 2002
12. Use of vegetable oil
(men 30-59)
70
North Karelia
60
Kuopio
Turku/Loimaa
50
Helsinki/Vantaa
Oulu
40
Lapland
30
20
10
0
1972 1977 1982 1987 1992 1997 2002
13. 24-h sodium excretion as NaCl
20
Men, North Karelia
18
Men, Kuopio area
Men, Southwestern Finland
Men, Helsinki area
16
Women, North Karelia
Women, Kuopio area
14
NaCl g
Women, Southwestern Finland
Women, Helsinki area
12
10
8
6
1979 1982 1987 2002
YEAR
Laatikainen et al. Eur J Clin Nutr 2006
14. Comparing the observed male mortality rates from CHD in N.E.
Finland with those predicted from changes in the risk factors.
0
Smoking
-10
Blood
pressure
-20
Percent decline
Cholesterol
-30
-40
All three
risks
-50
Observed
mortality
-60
-70
1975 1980 1985 1990
Vartiainen et al. 1994.
15. DPS: The Finnish Diabetes Prevention Study
The main aim:
To determine whether lifestyle intervention of overweight,
middle-aged subjects with impaired glucose tolerance
(IGT) will prevent or delay the development of type 2
diabetes
Study subjects:
• 522 subjects with IGT in two oral glucose tolerance tests
• Age 40–65 years
• BMI > 25 kg/m2
• Randomization to standard care control group or
intensive lifestyle intervention group
N Engl J Med 2001; 344:1343
17. Reduction of the incidence of diabetes during the
lifestyle intervention - DPS
1.0
0.9
0.8
0.7
0.6
Risk reduction: 58%
0.5
Intervention 0 1 2 3 4 5 6
group
Control group Year
18. DPS: Diabetes incidence
by the randomization group
during the total extended follow-up period
50
Log-rank test: p=0.0001
Cumulative incidence of T2D, %
Control
Hazard ratio=0.57 (95% CI 0.43-0.76)
40
30
20
Intervention
10
Intervention ceased
0
0 1 2 3 4 5 6 7 8
Follow-up time, years
Lindström et. al. Lancet 2006;368:1673-79
19. Changes in clinical and metabolic
parameters1
% 8
p<0.001
6
p=0.001
4
2 p<0.001 p<0.001
p<0.001 p<0.001 p=0.014 p=0.006
0
p=0.002
-2
-4
-6
-8
-10
-12
Weight Waist fPG 2-h PG fINS TG HDL SYST DIAS
1frombaseline to year 1
Intervention Control subjects with the MetS
20. Proportion of subjects becoming diabetic by success in
achieving the intervention targets at one-year
examination - DPS
50
% 45
40 Intervention Control
35
30
25
20
15
10
5
0
0 1 2 3 4 5
SUCCESS SCORE
21. 1-year lifestyle changes in the Intervention and
Control groups by FINDRISC
% 10,00
8,00
6,00
4,00
2,00
0,00
-2,00
-4,00
-6,00
Weight % Fat E% SaFat E% Fibre g / Exercise
1000kcal min/day
Intervention, low FINDRISC Intervention, high FINDRISC
Control, low FINDRISC Control, high FINDRISC
p for interaction (FINDRISC*group) ns for all
22. Change in total duration of leisure-time physical activity and
the reduction in incidence of diabetes – DPS:
the highest tertile (3.8 h/wk) versus the lowest tertile (-3.2 h/wk)
Model 1 Model 2 Model 3*
0
-10
Risk reduction (%)
-20
-30
-40
-50
-60
-70
-80
-90
* Adjusted for all baseline and follow-up variables
23. Change in duration of lifestyle leisure-time physical activity and
the reduction in reduction in incidence of diabetes -DPS:
the highest tertile (1.9 h/wk) versus the lowest tertile (-1.8 h/wk)
Model 1 Model 2 Model 3*
0
-10
Risk reduction (%)
-20
-30
-40
-50
-60
-70
-80
* Adjusted for all baseline and follow-up variables
24.
25.
26. Cumulative Incidence of Diabetes
100 HRR 0.57 (95% CI, 0.41 – 0.81)
93% 11.3% / yr
80
Percentage (%)
66% 80% 6.9% / year
60
40 43%
Control
Intervention
20
0
0 2 4 6 8 10 12 14 16 18 20
Years of follow up
*Age and cluster variable clinic adjusted
27. Cumulative Incidence of CVD Death
20 17%
1986-2006 HRR = 0.83 (95% CI 0.48 – 1.40) (0.9% / yr)
1993-2006 HRR = 0.73 (95% CI 0.42 – 1.26)
16
Percentage (%)
12 13%
Control (0.6 % / yr )
8 Intervention
4
0
0 2 4 6 8 10 12 14 16 18 20
Years of follow up
28. Hazard ratios for total and CVD mortality according
to leisure time activity among diabetic/IGT patients
- the Whitehall Study
Physical activity Total mortality CVD mortality
Low 1.65 (1.1-2.5) 3.60 (1.6-8.0)
Moderate 1.59 (1.1-2.4) 2.47 (1.1-5.4)
High 1.0 1.0
P for trend 0.03 0.02
Adjusted for age, BMI, systolic blood pressure, cholesterol, smoking and
disease at study entry.
Batty et al. Diabet Med 2002;19:580–8.
29. Physical activity and CVD mortality
among patients with type 2 diabetes –
The FINRISK Study
30. Multivariate-adjusted hazard ratios for total and
CVD mortality among diabetic patients
- occupational physical activity
Occupational Total mortality CVD mortality
physical activity
Low 1.00 1.00
Moderate 0.86 (0.74-1.00) 0.91 (0.75-1.10)
Active 0.60 (0.52-0.69) 0.60 (0.50-0.71)
P for trend <0.001 <0.001
Adjusted for age, sex, study year, BMI, systolic blood pressure, cholesterol,
smoking, and other two types of physical activity
Hu et al. Circulation 2004;110:666-73.
31. Multivariate-adjusted hazard ratios for total and
CVD mortality among diabetic patients
- commuting physical activity
Walking or Total mortality CVD mortality
cycling to work
0 1.00 1.00
1-29 min/d 0.82 (0.71-0.94) 0.81 (0.67-0.96)
>=30 min/d 0.75 (0.64-0.87) 0.74 (0.61-0.90)
P for trend <0.001 0.002
Adjusted for age, sex, study year, BMI, systolic blood pressure, cholesterol,
and smoking.
Hu et al. Circulation 2004;110:666-73.
32. Multivariate-adjusted hazard ratios for total and
CVD mortality among diabetic patients
- leisure-time physical activity
Leisure-time Total mortality CVD mortality
physical activity
Low 1.00 1.00
Moderate 0.82 (0.73-0.91) 0.83 (0.72-0.95)
High 0.71 (0.56-0.92) 0.67 (0.49-0.93)
P for trend <0.001 0.005
Adjusted for age, sex, study year, BMI, systolic blood pressure, cholesterol,
smoking, and other two types of physical activity
Hu et al. Circulation 2004;110:666-73.
33.
34.
35.
36.
37.
38. Risk of AMI associated with Quartiles of Dietary Patterns
(95% CI) - INTERHEART
2.0 Age and for ageadj sex
sex and
Adjusted
Plus region, educ, BMI, physical activity,activity, smokingadj
Adjusted for age, sex, and region, education, BMI, physical smoking
Adjusted for all Interheart risk factors
All INTERHEART risk factors adj
Odds Ratio
1.0
0.5
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Oriental Dietary Pattern Western Dietary Pattern Prudent Dietary Pattern
Quartile Iqbal et al. Unpublished
39. Risk of AMI associated with Quartiles of Dietary Risk Score
(DRS) (95% CI) after adj for age, sex, region - INTERHEART
4.0
Overall
Overall
Women
Women
Men
Men
Odds Ratio
2.0
1.0
0.5
Q 1 Q2 Q3 Q4 Q1 Q 2 Q3 Q4 Q1 Q2 Q3 Q4
Overall Women Men
Score Quartile
Iqbal et al. Unpublished
40. OR (95% CI)
Population Attributable Risk and Odds Ratios for AMI
associated with Dietary Risk Score- INTERHEART
OR
PAR
Q4 vs Q1
0.30 1.92
Overalla
(0.26-0.35) (1.74-2.11)
0.28 1.90
Maleb
(0.23-0.33) (1.70-2.11)
0.39 2.55
Femaleb
(0.30-0.49) (2.00-3.23)
N. America, W.
0.30 2.12
Europe
(0.17-0.42) (1.61-2.78)
and Australiac
0.31 1.61
Central Europec
(0.18-0.44) (1.20-2.15)
0.28 1.81
Middle Eastc
(0.17-0.40) (1.41-2.33)
0.10 1.27
Africac
(-0.14-0.35) (0.82-1.97)
0.29 1.85
South Asiac
(0.18-0.40) (1.46-2.34)
0.18 2.02
Chinac
(0.07-0.29) (1.65-2.48)
0.58 4.27
Southeast Asiac
(0.45-0.71) (2.87-6.35)
0.15 1.80
S. Americac
(-0.03-0.32) (1.30-2.49)
a adjusted for age, sex and regions 0.5 1 2 4 8
b adjusted for age and regions
c Adjusted for age and sex
OR (95% CI) Iqbal et al.